Treatment of lung cancer has moved towards individualized treatment using the combined assessment of immunohistochemical markers, mutational analyses, and FISH techniques in order to assess the exact histology and to detect, for example, KRAS and EGFR mutations or ALK translocations [6, 8, 20]. This evidence concerns the gene KRAS and lung carcinoma.